0001209191-22-039649.txt : 20220628 0001209191-22-039649.hdr.sgml : 20220628 20220628172510 ACCESSION NUMBER: 0001209191-22-039649 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220625 FILED AS OF DATE: 20220628 DATE AS OF CHANGE: 20220628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McClung David Mark CENTRAL INDEX KEY: 0001811505 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 221051139 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001811505 McClung David Mark C/O SANGAMO THERAPEUTICS, INC. 7000 MARINER BLVD. BRISBANE CA 94005 0 1 0 0 EVP, Chief Operating Officer Common Stock 2022-06-25 4 F 0 11525 4.31 D 175816 D Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on June 25, 2022 which were surrendered by the Reporting Person to the Issuer solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 24, 2022 of $4.31/share pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. Includes: (a) 21,805 shares resulting from the June 25, 2022 vesting of the Reporting Person's June 25, 2020 RSU grant and 33,340 shares subject to such RSU grant that will vest in one final annual installment on June 25, 2023, (b) 26,668 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 25, 2023 and 2024, respectively, and (c) 59,400 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Includes 2,357 shares acquired on May 31, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. David Mark McClung, by /s/ Ron A. Metzger, Attorney-in-Fact 2022-06-28